Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCiardiello, Fortunato
dc.contributor.authorCiardiello, Davide
dc.contributor.authorMartini, Giulia
dc.contributor.authorNapolitano, Stefania
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorCervantes, Andrés
dc.date.accessioned2022-09-12T08:22:48Z
dc.date.available2022-09-12T08:22:48Z
dc.date.issued2022-07
dc.identifier.citationCiardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022 Jul;72(4):372–401.
dc.identifier.issn1542-4863
dc.identifier.urihttp://hdl.handle.net/11351/8137
dc.descriptionImmunoteràpia; Càncer colorectal metastàtic; Medicina de precisió
dc.description.sponsorshipFortunato Ciardiello was supported by a grant from Regione Campania (I-Cure Research Project Cup 21C17000030007). Andres Cervantes was supported by grants from the Instituto de Salud Carlos III (PI18/01909 and PI21/00689). Fortunato Ciardiello reports institutional research grants from Amgen, Merck KGaA, Merck Sharp & Dohme, Pfizer, Pierre Fabre, Roche, and Servier; and service on advisory boards for Bayer, Merck KGaA, Merck Sharp & Dohme, Pierre Fabre, Roche, and Servier outside the submitted work. Davide Ciardiello reports a travel grant from Sanofi outside the submitted work. Stefania Napolitano reports honoraria from Bristol Myers Squibb and Novartis outside the submitted work. Josep Tabernero reports advisory board or scientific consultancy fees from Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Roche, Genentech, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck KGaA, Merus, Merck Sharp & Dohme, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, SotioBiotech, Taiho, Tessa Therapeutics, and TheraMyc outside the submitted work. Andres Cervantes reports institutional research grants from Genentech, Merck KGaA, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Takeda, and Fibrogen; and honoraria or speaker’s fees from Amgen, Merck KGaA, Roche, Bayer, Servier, and Pierre Fabre outside the submitted work. Giulia Martini reports no conflicts of interest.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesCA: A Cancer Journal for Clinicians;72(4)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCòlon - Càncer - Tractament
dc.subjectRecte - Càncer - Tractament
dc.subjectMedicina personalitzada
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/therapy
dc.subject.meshPrecision Medicine
dc.titleClinical management of metastatic colorectal cancer in the era of precision medicine
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3322/caac.21728
dc.subject.decsneoplasias colorrectales
dc.subject.decs/terapia
dc.subject.decsmedicina de precisión
dc.relation.publishversionhttps://doi.org/10.3322/caac.21728
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ciardiello F, Martini G, Napolitano S] Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. [Ciardiello D] Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Division of Medical Oncology, IRCCS Foundation Home for the Relief of Suffering, San Giovanni Rotondo, Italy. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology, University of Vic/Central University of Catalonia, Barcelona, Spain. Oncology Institute of BarcelonaQuironsalud, Biomedical Research Center in Cancer, Barcelona, Spain. [Cervantes A] Medical Oncology Department, Instituto de Investigación Sanitaria Valencia Biomedical Research Institute, University of Valencia, Valencia Spain. Carlos III Institute of Health, Biomedical Research Center in Cancer, Madrid, Spain
dc.identifier.pmid35472088
dc.identifier.wos000787357900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple